Search results

69 results

Sorted by Relevance . Sort by Date

  1. In those patients with a new diagnosis of hypertension or type 2 diabetes aged 25-84 years, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, stroke and/or TIA), who have a recorded CVD risk assessment score (using the QRISK2 assessment tool) of more than 20% in the preceding 12 months: the percentage who are currently treated with statins (unless there is a contraindication)

    In those patients with a new diagnosis of hypertension or type 2 diabetes aged 25-84 years, recorded between the preceding 1 April to 31 March...

  2. The percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: assessment of stroke/VTE risk; assessment of bleeding risk; assessment of renal function, creatinine clearance, FBC and LFTs as appropriate for their anticoagulation therapy; any adverse effects related to anticoagulation; assessment of compliance; choice of anticoagulant

    The percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which...

  3. The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia with a FAST score of 3 or more or AUDIT-C score of 5 or more in the preceding 2 years who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded

    The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or...

  4. The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more)

    The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring...

  5. The percentage of patients registered at the practice aged 65 years and over who have been diagnosed with one or more of the following conditions: coronary heart disease, heart failure, hypertension, diabetes, CKD, PAD, or stroke/TIA who have had a pulse rhythm assessment in the preceding 12 months.

    The percentage of patients registered at the practice aged 65 years and over who have been diagnosed with one or more of the following conditions:...

  6. The percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel) (or anticoagulant drug therapy) and a statin and a beta-blocker for those patients with left ventricular systolic dysfunction

    The percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if...

  7. The percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with ACE-I (or ARB if ACE-I intolerant), dual anti-platelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction

    The percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with ACE-I (or ARB

  8. NICE signs up to join the GetReal Institute

    NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.

  9. Starting with the end in mind - the Innovative Licensing and Access Pathway

    Launched in January, the new Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS. It is an exciting development that signals greater collaboration between the agencies involved and, we hope, should bring significant benefits to patients.

  10. NICE welcomes appointment of six new Board members

    NICE is delighted with today’s (15 March) announcement from the Department of Health & Social Care appointing six new non-executive directors to its Board following their approval by the Secretary of State.